Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Boston Therapeutics, Inc. (BTHE) Tackles One Of America's Greatest Epidemics 0 comments
    Jan 6, 2014 5:28 PM | about stocks: BTHE

    It's turning out to be one of the biggest epidemic waves in American history, with estimated costs nationally jumping approximately 40% in just the past 5 years, to roughly $1/4 trillion annually. The epidemic is diabetes, and the size and scope of the problem, including the disastrous drain on the country's economy, is just now beginning to be fully appreciated. Less obvious and dramatic than high-profile diseases such as cancer, the hidden power behind the diabetes epidemic is that it affects so many people. It is now estimated that over 25 million Americans have the disease, though many are not aware of it, with nearly 80 million Americans in a state of prediabetes. Diabetes complications include heart disease, stroke, kidney damage, and retinopathy.

    Driven, it is believed, by a generation of negative dietary and life style habits, diabetes is now becoming one of America's primary healthcare targets. Unfortunately, such habits, and the industries that support them, are slow to change, and today there is a desperate need for medical technologies that can help stem the epidemic tide more quickly.

    Boston Therapeutics believes it has developed the most effective single solution with PAZ320, the company's non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. The drug is currently undergoing clinical trials after getting promising results in initial studies. PAZ320 would be a miracle to millions of diabetic and prediabetic patients, or anyone seeking to better manage blood glucose levels, by inhibiting the enzymes that release glucose from complex carbohydrates in foods during digestion. As a result, the drug now has a near-term opportunity in what is already a $35 billion diabetes drug market.

    PAZ320 is not Boston Therapeutic's only product. They are also in pre-clinical stage development of IPOXYN, an injectable universal oxygen carrier for the prevention of necrosis and treatment of ischemic conditions which may lead to necrosis, and OxyFex, a veterinary facsimile to Ipoxyn.

    For additional information, visit BostonTI.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: BTHE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.